The START Center for Cancer Research has dosed the first US participant in Moderna’s phase 1 clinical trial evaluating mRNA-4106, an investigational pan-tumour antigen therapy in patients with advanced or metastatic solid tumours. The first dose was administered at START’s San Antonio site in the US, as part of a study assessing the safety, pharmacodynamics, […] The post Moderna doses first US patient in phase 1 trial of mRNA-4106 for solid tumo…
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.